GlassScriptPhysician profile
George Burgess
NPI 1376847210
$13,693.21
in general payments reported to CMS, 2019-2025
39 companies · $3,421 in 2025
The $3,421 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $865 · 2022: $1,632 · 2023: $4,784 · 2024: $2,992 · 2025: $3,421.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,241 · Travel and Lodging: $1,699 · Education: $256.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,241.47 |
| Travel and Lodging | $1,698.56 |
| Education | $255.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $2,191.52 | 2021-2025 | Inspire |
| Zoll Respicardia, INC. | $1,416.30 | 2023-2025 | Remede System |
| Glaxosmithkline, LLC. | $1,335.43 | 2021-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Astrazeneca Pharmaceuticals LP | $1,131.21 | 2021-2025 | Fasenra, Airsupra, Breztri |
| United Therapeutics Corporation | $880.58 | 2021-2025 | Tyvaso, Tyvaso |
| Boehringer Ingelheim Pharmaceuticals, INC. | $877.60 | 2021-2025 | Ofev, Jascayd, Spiriva Respimat |
| Actelion Pharmaceuticals US, INC. | $773.79 | 2021-2025 | Uptravi, Opsumit |
| Harmony Biosciences LLC | $734.95 | 2022-2025 | Wakix |
| Insmed, INC. | $649.07 | 2021-2025 | Arikayce, Brinsupri |
| Takeda Pharmaceuticals U.S.A., INC. | $486.46 | 2021-2025 | Glassia |
| Jazz Pharmaceuticals INC. | $340.48 | 2021-2025 | |
| Genzyme Corporation | $271.73 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $253.67 | 2021-2025 | Dupixent |
| Amgen INC. | $210.31 | 2021-2025 | Tezspire |
| Mallinckrodt Hospital Products INC. | $203.67 | 2023-2025 | Acthar |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $174.61 | 2023-2025 | Sunosi |
| Inogen, INC. | $171.37 | 2023-2024 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Lilly USA, LLC | $170.85 | 2025 | Zepbound, Mounjaro |
| Fresenius USA Marketing, INC. | $162.00 | 2021-2023 | Velphoro |
| Astellas Pharma US INC | $160.46 | 2023 | Cresemba |
| Avadel Cns Pharmaceuticals, LLC | $146.88 | 2024-2025 | Lumryz |
| Electromed, INC. | $137.79 | 2024-2025 | Smartvest |
| Grifols USA, LLC | $137.50 | 2024-2025 | Prolastin-C Liquid |
| Vifor Pharma, INC. | $92.53 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $76.45 | 2021-2025 | Winrevair |
| Abbott Laboratories | $71.70 | 2025 | Cardiomems |
| Mylan Specialty L.P. | $65.05 | 2024 | Yupelri |
| Otsuka America Pharmaceutical, INC. | $62.86 | 2021-2022 | |
| Baxter Healthcare | $47.61 | 2022-2024 | Hillrom - Vest System Model 105 Home Care |
| Viatris Specialty LLC | $43.71 | 2025 | Yupelri |
| Novartis Pharmaceuticals Corporation | $36.21 | 2025 | |
| Idorsia Pharmaceuticals US INC | $31.51 | 2023 | Quviviq |
| Philips North America LLC | $30.56 | 2022-2023 | |
| Fisher & Paykel Healthcare INC | $22.12 | 2023 | Fisher & Paykel Healthcare |
| Janssen Pharmaceuticals, INC | $21.84 | 2023 | Xarelto |
| Genentech USA, INC. | $20.52 | 2021 | |
| Paratek Pharmaceuticals, INC. | $18.22 | 2024 | Nuzyra |
| Teva Pharmaceuticals USA, INC. | $18.11 | 2021 | |
| Verona Pharma, INC. | $15.98 | 2025 | Ohtuvayre |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Burgess listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.